Mild Hypothermia and Supplemental Magnesium Sulfate Infusion in Severe Traumatic Brain Injury (TBI) Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01333488
Recruitment Status : Terminated (Low accrual)
First Posted : April 12, 2011
Results First Posted : September 30, 2015
Last Update Posted : October 28, 2015
Information provided by (Responsible Party):
Greg Zorman, United States Department of Defense

April 8, 2011
April 12, 2011
August 4, 2015
September 30, 2015
October 28, 2015
December 2011
March 2014   (Final data collection date for primary outcome measure)
GOS (Glasgow Outcome Score) [ Time Frame: Discharge from Hospital - Within 2 months from Injury ]

GOS=5 (Good Recovery) - Capacity to resume normal occupational and social activities, although some there may be some minor physical or mental deficits or symptoms.

GOS=4 (Moderate Disability) - Independent and can resume almost all activities of daily living.

GOS=3 (Severe Disability) - No longer capable of engaging in most previous personal, social or work activities. Typically are partially or totally dependent on assistance from others in daily living.

GOS=2 ( Persistent Vegetative State ) GOS=1 (Dead)

Same as current
Complete list of historical versions of study NCT01333488 on Archive Site
  • GOS [ Time Frame: 12 months after injury ]
    GOS score
  • Vasospasm [ Time Frame: up to 3 months ]
    as measured by TCD (Transcranial Doppler)
  • GOS [ Time Frame: 3, 6 and 12 months after injury ]
  • Vasospasm [ Time Frame: ongoing ]
    as measured by TCD (Transcranial Doppler)and transcranial arteriography
Not Provided
Not Provided
Mild Hypothermia and Supplemental Magnesium Sulfate Infusion in Severe Traumatic Brain Injury (TBI) Subjects
A Phase 2, Randomized, Controlled 2x3 Trial Comparing Clinical Outcomes in Patients With Severe Traumatic Brain Injury Using Mild Hypothermia and Concurrent and Supplemental Infusion of Magnesium Sulfate.

The investigators hypothesize that hypothermia (body cooling) and additional magnesium sulfate will improve the outcome of severe Traumatic Brain Injury (TBI) patients.

This is a study to compare the outcomes of patients with severe traumatic brain injury who have been allocated to one of the following three groups:

Group 1 - Conventional therapy following traumatic brain injury Group 2 - Subjects will have their core body temperature lowered to 34C Group 3 - Subjects will have their core body temperature lowered to 34C and will receive a supplemental intravenous infusion of magnesium sulfate.

Not Provided
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Traumatic Brain Injury
  • Device: Arctic Sun
    Core Body Temperature will be lowered using an Arctic Sun device to 34C. Bladder probe will monitor core temperature.
  • Drug: Magnesium Sulfate
    IVI drug levels of Magnesium Sulfate targeted to plasma levels of magnesium of 2.5-3.5 mEq/Liter.(1.25-1.75mmol/L; or 3.04 - 4.26mg/dL)for 72 hours.
  • No Intervention: Conventional Therapy
  • Experimental: Hypothermia
    Subjects will have their core body temperatures lowered to 34C.
    Intervention: Device: Arctic Sun
  • Experimental: Hypothermia plus supplemental magnesium sulfate infusion
    • Device: Arctic Sun
    • Drug: Magnesium Sulfate
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
June 2014
March 2014   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Adult males or females ≥ 18 years of age
  2. Subjects with Traumatic Brain Injury and a post-resuscitation Glasgow Coma Score (GCS) ≤ 8
  3. In-hospital and screened within 7 hours of injury.
  4. Able to obtain legally effective written consent from authorized representative
  5. Patients who are intubated and on mechanical ventilation
  6. Admitted to ICU

Exclusion Criteria:

  1. Bladder or rectal core temperature below 32C (89.6F) upon admission
  2. Clinical brain death
  3. Patients with open abdomens.
  4. Multiple orthopedic injuries (> 2 long bone fractures)
  5. Persistent hypotension (systolic blood pressure < 90mmHg)
  6. Persistent hypoxia (O2 Saturation < 94%)
  7. Persistent metabolic acidosis (Lactic acid > 5 mmol/L, arterial pH < 7.25)
  8. Positive serum pregnancy test
  9. Cardiac arrhythmia with deleterious hemodynamic effects; heart block or myocardial damage (as shown on ECG)
  10. History of abnormal renal function
  11. Significant Co-morbidity (i.e. CAD;COPD; severe coagulopathy)
  12. Pediatric patients (< 18 years old)
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
United States
Not Provided
Not Provided
Greg Zorman, United States Department of Defense
United States Department of Defense
Not Provided
Principal Investigator: Greg Zorman, MD Memorial Healthcare System
United States Department of Defense
October 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP